Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Acute Myeloid Leukemia (AML)

 

CPX-351 Versus 7+3 for Older Patients (2651)
Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01696084

Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML

Investigator: Derek L. Stirewalt, MD;   Conditions: Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01607645

Bortezomib for High-Risk Acute Myeloid Leukemia in Remission
A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Closed;   Study ID: NCT01465386

Tosedostat with Cytarabine or Decitabine for AML
A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01567059

GSK2130579A for Acute Myeloid Leukemia (AML) (WT1-AS01B-AML-001)
Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients in First Complete Remission

Investigator: Elihu Estey, MD;   Conditions: WT1-positive Acute Myeloid Leukemia;    Status: Closed;   Study ID: NCT00725283

Clofarabine + Cytarabine for Older Patients With AML (FHCRC-2302)
A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age

Investigator: John Pagel, MD;   Conditions: Acute Myeloid Leukemia;    Status: Closed;   Study ID: NCT00839982

Chemotherapy + AntiCXR4 for Relapsed or Refractory AML (UW09036)
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia

Investigator: Pamela S. Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Closed;   Study ID: NCT01120457

AC220 Post Transplant for Acute Myeloid Leukemia (2487)
A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant

Investigator: Brenda Sandmaier, MD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Closed;   Study ID: NCT01468467

Radioimmunotherapy + SCT for Advanced AML, ALL, or MDS
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate

Investigator: John M. Pagel, MD;   Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome;    Status: Recruiting;   Study ID: NCT00988715

Adoptive Immunotherapy for Relapsed AML, MDS, or CML (FH 2498)
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML

Investigator: Merav Bar, MD;   Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia;    Status: Recruiting;   Study ID: NCT01640301

Decitabine + Mitoxantrone Hydrochloride, Etoposide, and Cytarabine for AML or MDS (2652)
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes;    Status: Recruiting;   Study ID: NCT01729845

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients (2572)
A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia

Investigator: John Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML);    Status: Recruiting;   Study ID: NCT01756677

Bendamustine Hydrochloride and Idarubicin for Previously Untreated AML or MDS (2413)
Safety and Clinical Activity of TreandaTM (Bendamustine HCL) and Idarubicin in Combination Therapy for Patients Over Age 60 with Previously Untreated Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (MDS)

Investigator: John M. Pagel, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia;    Status: Closed;   Study ID: NCT01141725

Clofarabine, Cytarabine, and G-CSF for Newly Diagnosed Acute Myeloid Leukemia or Advanced MDS (7144)
Phase 2 Study Of Clofarabine With High Dose Cytarabine And G-CSF Priming In Adult Patients Under Age 60 With Newly Diagnosed Acute Myeloid Leukemia Or Advanced Myelodysplastic Syndrome

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS);    Status: Closed;   Study ID: NCT01101880

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride for Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) (2734)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Investigator: Roland Walter, MD;   Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD);    Status: Recruiting;   Study ID: NCT02044796

AMG 232 for Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Investigator: Pamela Becker, MD, PhD;   Conditions: Acute Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT02016729